The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nivolumab (NIVO) + relatlimab (RELA) versus NIVO in previously untreated metastatic or unresectable melanoma: OS and ORR by key subgroups from RELATIVITY-047.
 
Hussein A. Tawbi
Consulting or Advisory Role - Array BioPharma; Boxer Capital; Bristol-Myers Squibb; Eisai; Genentech/Roche; Iovance Biotherapeutics; Jazz Pharmaceuticals; Karyopharm Therapeutics; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Dragonfly Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); RAPT Therapeutics (Inst)
 
F. Stephen Hodi
Employment - Dana-Farber Cancer Institute
Leadership - Bicara Therapeutics
Stock and Other Ownership Interests - Apricity Health; Bicara Therapeutics; Pionyr; Torque
Consulting or Advisory Role - Amgen; Bioentre; Boston Pharmaceuticals; Bristol-Myers Squibb; Catalym; Checkpoint THerapeutics; Compass Therapeutics; Eisai; EMD Serono; Genentech/Roche; Gossamer Bio; Immunocore; Iovance Biotherapeutics; Merck Sharp & Dohme; Novartis; Partners Therapeutics; Pionyr; Rheos Medicines; Sanofi; Surface Oncology; Torque; Trillium Therapeutics
Research Funding - bristol-myers squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); novartis (Inst)
Patents, Royalties, Other Intellectual Property - Angiopoietin-2 Biomarkers Predictive of Anti-immune checkpoint response (Inst); Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Melanoma using PD-L1 Isoforms; Methods of Using Pembrolizumab and Trebananib (Inst); patent pending as per institutional policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
Other Relationship - Bristol-Myers Squibb; Genentech/Roche
 
Evan J. Lipson
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Genentech; Instil Bio; Macrogenics; Merck; Natera; Nektar; Novartis; Odonate Therapeutics; OncoSec; Pfizer; Rain Therapeutics; Sanofi/Regeneron
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst); Sanofi/Regeneron (Inst)
 
Dirk Schadendorf
Honoraria - 4SC; Amgen; Array BioPharma; Bristol-Myers Squibb; Daiichi Sankyo Japan; Immunocore; InflarxGmbH; LabCorp; Merck Serono; Merck Sharp & Dohme; Nektar; NeraCare GmbH; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Replimune; Roche/Genentech; Sandoz; Sanofi/Regeneron; Sun Pharma; Ultimovacs
Consulting or Advisory Role - 4SC; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; NEKTAR; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
Speakers' Bureau - Bristol-Myers Squibb; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi/Regeneron
Research Funding - Amgen (Inst); Array BioPharma/Pfizer (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
 
Paolo Antonio Ascierto
Stock and Other Ownership Interests - PrimeVax
Consulting or Advisory Role - 4SC; Alkermes; Array BioPharma; AstraZeneca; Bio-AI Health; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Idera; Immunocore; Incyte; Italfarmaco; ITeos Therapeutics; Lunaphore Technologies; Medicenna; MedImmune; Merck Serono; Merck Sharp & Dohme; Nektar; Nouscom; Novartis; OncoSec; Pfizer; Pierre Fabre; Regeneron; Roche/Genentech; Sandoz; Sanofi; Seagen; Sun Pharma; Takis Biotech; Ultimovacs
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Luis Matamala
Employment - Arturo Lopez Perez Foundation
 
Pamela Salman
No Relationships to Disclose
 
Erika Castillo Gutiérrez
No Relationships to Disclose
 
Piotr Rutkowski
Honoraria - Bristol-Myers Squibb; Merck; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Amgen; Blueprint Medicines; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
Speakers' Bureau - Novartis; Pfizer; Pierre Fabre
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Orphan Europe; Pierre Fabre
 
Helen Gogas
Honoraria - Bristol-Myers Squibb; MSD Oncology; Pierre Fabre; Sanofi/Regeneron
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD Oncology; Pierre Fabre; Sanofi/Regeneron
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Iovance Biotherapeutics (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MSD; Pfizer
 
Christopher D. Lao
Research Funding - Bristol-Myers Squibb; Genentech; Novartis; Oncosec
 
Juliana Janoski De Menezes
No Relationships to Disclose
 
Stéphane Dalle
Employment - Sanofi Pasteur (I)
Stock and Other Ownership Interests - Sanofi (I)
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); MSD (Inst)
Speakers' Bureau - Bristol-Myers Squibb (Inst); MSD (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Ana Maria Arance
Consulting or Advisory Role - BMS; Merck; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Speakers' Bureau - BMS; Merck; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Research Funding - BMS (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - BMS; MSD; Novartis; Pierre Fabre
 
Jean-Jacques Grob
Consulting or Advisory Role - Amgen; BMS; Merck KGaA; MSD Oncology; Novartis; Philogen; Pierre fabre; Roche; Roche/Genentech; Sanofi; Sun Pharma
Speakers' Bureau - Novartis
Travel, Accommodations, Expenses - BMS; MSD Oncology; Novartis; Pierre Fabre
 
Sarah Keidel
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Karin Jonczak
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Anne Marie Sobiesk
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Sonia Dolfi
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Georgina V. Long
Honoraria - BMS; Pierre Fabre
Consulting or Advisory Role - Agenus; Amgen; Array BioPharma; Boehringer Ingelheim; Bristol-Myers Squibb; Evaxion Biotech; Hexal; Highlight Therapeutics; Merck Sharpe & Dohme; Novartis; OncoSec; Pierre Fabre; Provectus; QBiotics; Regeneron; Skyline Diagnostics